Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Coping with extreme climate and geopolitical uncertainty
Thriving in the face of hyper-volatility means building financial resilience using a combination of quantitative analytics and qualitative ‘storytelli
Longevity Perspectives
Industry experts Huey Fang Chen, Head of L&H Structured Solutions Asia, and Kerry McMullan, Global Head of L&H Structured Solutions, explore global tr
Advancing Data Driven Decision Making in 2026
As the general insurance landscape continues to evolve in response to shifting and growing risks, one constant remains: the need for sharper insights

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.